Sarpogrelate hydrochloride decreases cardio-ankle vascular index accompanied by increased serum lipoprotein lipase mass in type 2 diabetic patients

International Heart Journal

Volumn 55, Issue 4, 2014, Pages 337-341

  Nagayama, Daiji ^a   Ohira, Masahiro ^a   Saiki, Atsuhito ^a   Shirai, Kohji ^a   Tatsuno, Ichiro ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Diabetic angiopathy

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SARPOGRELATE; TRIACYLGLYCEROL;

AGED; ARTERIAL STIFFNESS; ARTICLE; BODY MASS; CARDIO ANKLE VASCULAR INDEX; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; COLD; DIABETIC ANGIOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PARESTHESIA; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; ANKLE BRACHIAL INDEX; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN RESISTANCE; LIPOPROTEIN LIPASE; MALE; SEROTONIN ANTAGONISTS; SUCCINATES; TREATMENT OUTCOME; VASCULAR STIFFNESS;

EID: 84899493868     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.13-377     Document Type: Article

References (33)

1. Hara H, Osakabe M, Kitajima A, Tamao Y, Kikumoto R. MCl-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb Haemost 1991; 65: 415-20.
2. Nonogaki K, Nozue K, Oka Y. Increased hypothalamic 5-HT2A receptor gene expression and effects of pharmacologic 5-HT2A receptor inactivation in obese Ay mice. Biochem Biophys Res Commun 2006; 29; 351: 1078-82.
3. Sun YM, Su Y, Jin HB, Li J, Bi S. Sarpogrelate protects against high glucose-induced endothelial dysfunction and oxidative stress. Int J Cardiol 2011; 147: 383-7.
4. Kokubu N, Tsuchihashi K, Yuda S, et al. Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease. Circ J 2006; 70: 1451-6.
5. Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb 2006; 13: 101-7.
6. Yambe T, Meng X, Hou X, et al. Cardio-ankle vascular index (CAVI) for the monitoring of the atherosclerosis after heart transplantation. Biomed Pharmacother 2005; 59: S177-9.
7. Kubozono T, Miyata M, Ueyama K, et al. Clinical significance and reproducibility of new arterial distensibility index. Circ J 2007; 71: 89-94.
8. Nakamura K, Tomaru T, Yamamura S, Miyashita Y, Shirai K, Noike H. Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ J 2008; 72: 598-604.
9. Suzuki J, Sakakibara R, Tomaru T, et al. Stroke and cardio-ankle vascular stiffness index. J Stroke Cerebrovasc Dis 2013; 22: 171-5.
10. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008; 31: S55-60.
11. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus (2010) Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 2010; 53: 450-67.
12. Shirai K, Nema T, Hiroh Y, Itoh Y, Miyashita Y, Watanabe H. Clinical efficacy of the direct assay method using polymers for serum high density lipoprotein cholesterols. J Clin Lab Anal 1997; 11: 82-6.
13. Kobayashi J, Hashimoto H, Fukamachi I, et al. Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin Chem Acta 1993; 216: 113-23.
14. Hasegawa M, Rodbard S. Effect of posture on arterial pressures, timing of the arterial sounds and pulse wave velocities in the extremities. Cardiology 1979; 64: 122-32.
15. Yambe T, Yoshizawa M, Saijo Y, et al. Brachio-ankle pulse wave velocity and cardio-ankle vascular index (CAVI). Biomed Pharmacother 2004; 58: S95-8. (Review)
16. Nilsson-Ehle P, Garfinkel AS, Schotz MC. Lipolytic enzymes and plasma lipoprotein metabolism. Annu Rev Biochem 1980; 49: 667-93. (Review)
17. Ong JM, Kirchgessner TG, Schotz MC, Kern PA. Insulin increases the synthetic rate and messenger RNA level of lipoprotein lipase in isolated rat adipocytes. J Biol Chem 1998; 263: 12933-8.
18. Semenkovich CF, Wims M, Noe L, Etienne J, Chan L. Insulin regulation of lipoprotein lipase activity in 3T3-L1 adipocytes is mediated at post transcriptional and post-translational levels. J Biol Chem 1989; 264: 9030-8.
19. Saiki A, Oyama T, Endo K, et al. Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract 2007; 76: 93-101.
20. Nagayama D, Saiki A, Endo K, et al. Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients. Int J Clin Pract 2010; 64: 1796-801.
21. Watanabe H, Miyashita Y, Murano T, Hiroh Y, Itoh Y, Shirai K. Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias. Atherosclerosis 1999; 145: 45-50.
22. Shirai K, Itoh Y, Sasaki H, et al. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract 1999; 46: 35-41.
23. Takishita E, Takahashi A, Harada N, Yamato M, Yoshizumi M, Nakaya Y. Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model. J Cardiovasc Pharmacol 2004; 43: 266-70.
24. Nagayama D, Endo K, Ohira M, et al. Effects of body weight reduction on cardio-ankle vascular index (CAVI). Obes Res Clin Pract 2013; 7: e139-45.
25. Sun YM, Su Y, Jin HB, Li J, Bi S. Sarpogrelate protects against high glucose-induced endothelial dysfunction and oxidative stress. Int J Cardiol 2011; 17; 147: 383-7.
26. Hitsumoto T, Yoshinaga K, Noike H, Kanai M, Shirai K. Clinical significance of preheparin serum lipoprotein lipase mass in coronary vasospasm. Jpn Circ J 2001; 65: 539-44.
27. Perticone F, Ceravolo R, Pujia A, et al. Prognosis significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-6.
28. Endo K, Saiki A, Ohira M, Miyashita Y, Shirai K. Cardio-ankle vascular index may reflect endothelial function in type 2 diabetes. Int J Clin Pract 2011; 65: 1200-1.
29. Sharma SK, Del Rizzo DF, Zahradka P, et al. Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency. Ann Thorac Surg 2001; 71: 1856-64.
30. Nishihira K, Yamashita A, Tanaka N, et al. Serotonin induces vasoconstriction of smooth muscle cell-rich neointima through 5-hydroxytryptamine2A receptor in rabbit femoral arteries. J Thromb Haemost 2008; 6: 1207-14.
31. Shirai K, Song M, Suzuki J, et al. Contradictory effects of β1-and α1-aderenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI)--CAVI independent of blood pressure. J Atheroscler Thromb 2011; 18: 49-55.
32. Ishisone T, Koeda Y, Tanaka F, Sato K, Nagano M, Nakamura M. Comparison of utility of arterial stiffness parameters for predicting cardiovascular events in the general population. Int Heart J 2013; 54: 160-5.
33. Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007; 50: 197-203.